Combined PRF of the Pudendal Nerve With Ganglion Impar Block Effectively Alleviates Pudend
Patients with pudendal neuralgia suffer from long-term pain, which severely affects their quality of life. Due to unclear etiology, there is a lack of specific treatment methods. The aim of this study is to evaluate the efficacy of combined pulsed radiofrequency with ganglion impar block therapy helps evaluate the effe
| Condition(s) | Pudendal Neuralgia, Pulsed Radiofrequency |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Patients with pudendal neuralgia suffer from long-term pain, which severely affects their quality of life. Due to unclear etiology, there is a lack of specific treatment methods. The aim of this study is to evaluate the efficacy of combined pulsed radiofrequency with ganglion impar block therapy helps evaluate the effectiveness of this treatment method for pudendal neuralgia, comparing it with traditional treatments or single interventions, and providing guidance for clinical practice. |
| Who can participate | Inclusion Criteria: 1. Age between 18 and 80 years old; 2. Diagnosis of pudendal neuralgia meets the Nantes criteria. essential criteria include the following：1）Pain in the territory of the pudendal nerve；2） Pain is predominantly experienced while sitting；3) The pain does not wake the patient at night；4）Pain with no objective sensory impairment；5）Pain relieved by diagnostic pudendal nerve block； 3. Received conservative treatment for more than 3 months, and either had poor response to conservative treatment or intolerable medication side effects. 4. Capable of signing informed consent form. Exclusion Criteria: 1. Pain caused by pelvic malignant diseases or autoimmune diseases; 2. Pain caused by pelvic surgery; 3. Taking anticoagulant drugs or having abnormal coagulation function; 4. Pregna |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Peking University People's Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2023-05-01 |
| NCT ID | NCT06461312 |
| Official listing | https://clinicaltrials.gov/study/NCT06461312 |